Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG

Inclusion Criteria: * Histo-cytologically proven SCLC * Limited disease at diagnosis * Age greater than or equal to 18 * Patients with a clinical response of CR or PR to first line combined modality therapy * KPS greater than or equal to 60 * Adequate bone marrow, liver and heart functions * Written informed Consent Exclusion Criteria: * Prior surgical treatment for SCLC * History of tuberculosis * NCIC CTG grade 3 local skin toxicity reaction (ulceration) to \> IU PPD test \> 5 IU * HIV positive * Splenectomy or spleen radiation therapy in medical history * Prior therapy to proteins of murine origin * Any second line therapy for SCLC * Investigational agent or immune therapy within 4 weeks prior to study randomization * Severe active infections * Active infections requiring systemic antibiotics, antiviral, or antifungal treatments * Serious unstable chronic illness * The use of systemic anti-histamines, NSAID or systemic corticosteroids * Any previous malignancy except adequately treated CIS of the cervix or non melanoma skin cancer or if previous malignancy was more than 5 years prior and there are no signs of recurrence * Pregnancy or breast feeding or absence of adequate contraception for fertile patients * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before randomization in the trial.